Annexin A1 is involved in resistance to 5-FU in colon cancer cells

Oncology Reports

Volumn 37, Issue 1, 2017, Pages 235-240

  Onozawa, Hisashi ^a   Saito, Motonobu ^a   Saito, Katsuharu ^a   Kanke, Yasuyuki ^a   Watanabe, Yohei ^a   Hayase, Suguru ^a   Sakamoto, Wataru ^a   Ishigame, Teruhide ^a   Momma, Tomoyuki ^a   Ohki, Shinji ^a   Takenoshita, Seiichi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Annexin A1; Chemoresistance; Colon cancer; Proliferation

Indexed keywords

FLUOROURACIL; LIPOCORTIN 1; ANTINEOPLASTIC ANTIMETABOLITE;

ANXA1 GENE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR HYPOXIA;

ANNEXIN A1; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE KNOCKDOWN TECHNIQUES; HUMANS; TUMOR HYPOXIA;

EID: 85006482227     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.5234     Document Type: Article

References (24)

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66: 7-30, 2016.
2. Venook AP, Weiser MR and Tepper JE: Colorectal cancer: All hands on deck. Am Soc Clin Oncol Educ Book 34: 83-89, 2014.
3. Mayer RJ, Venook AP and Schilsky RL: Progress against GI cancer during the American Society of Clinical Oncology's first 50 years. J Clin Oncol 32: 1521-1530, 2014.
4. Rescher U and Gerke V: Annexins - unique membrane binding proteins with diverse functions. J Cell Sci 117: 2631-2639, 2004.
5. Lim LH and Pervaiz S: Annexin 1: The new face of an old molecule. FASEB J 21: 968-975, 2007.
6. Ydy LR, do Espírito Santo GF, de Menezes I, Martins MS, Ignotti E and Damazo AS: Study of the Annexin A1 and its associations with carcinoembryonic antigen and mismatch repair proteins in colorectal cancer. J Gastrointest Cancer 47: 61-68, 2016.
7. Duncan R, Carpenter B, Main LC, Telfer C and Murray GI: Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 98: 426-433, 2008.
8. Okano M, Kumamoto K, Saito M, Onozawa H, Saito K, Abe N, Ohtake T and Takenoshita S: Upregulated Annexin A1 promotes cellular invasion in triple-negative breast cancer. Oncol Rep 33: 1064-1070, 2015.
9. Sato Y, Kumamoto K, Saito K, Okayama H, Hayase S, Kofunato Y, Miyamoto K, Nakamura I, Ohki S, Koyama Y, et al: Upregulated Annexin A1 expression in gastrointestinal cancer is associated with cancer invasion and lymph node metastasis. Exp Ther Med 2: 239-243, 2011.
10. Wang Y, Serfass L, Roy MO, Wong J, Bonneau AM and Georges E: Annexin-I expression modulates drug resistance in tumor cells. Biochem Biophys Res Commun 314: 565-570, 2004.
11. Takahashi K, Tanaka M, Inagaki A, Wanibuchi H, Izumi Y, Miura K, Nagayama K, Shiota M and Iwao H: Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line. Int J Oncol 43: 1985-1991, 2013.
12. Anbalagan D, Yap G, Yuan Y, Pandey VK, Lau WH, Arora S, Bist P, Wong JS, Sethi G, Nissom PM, et al: Annexin-A1 regulates microRNA-26b. and microRNA-562 to directly target NF-κB and angiogenesis in breast cancer cells. PLoS One 9: e114507, 2014.
13. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, et al: Leucovorin and fluorouracil with or without oxaliplatin as firstline treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
14. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
15. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355: 1041-1047, 2000.
16. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
17. Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003.
18. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
19. Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL and Dang CV: Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem 276: 7919-7926, 2001.
20. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC and Harris AL: Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85: 881-890, 2001.
21. Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, Han S, Liu J, Sun S, Han Z, et al: Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 99: 121-128, 2008.
22. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV and Neckers LM: Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392: 405-408, 1998.
23. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL and Bedi A: Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14: 34-44, 2000.
24. Chen J, Ding Z, Peng Y, Pan F, Li J, Zou L, Zhang Y and Liang H: HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein. PLoS One 9: e98882, 2014.